41O Stock Overview
Operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Outlook Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.60 |
| 52 Week High | US$9.52 |
| 52 Week Low | US$0.84 |
| Beta | 0.59 |
| 1 Month Change | -21.57% |
| 3 Month Change | -67.61% |
| 1 Year Change | -78.95% |
| 3 Year Change | -93.87% |
| 5 Year Change | -89.33% |
| Change since IPO | -96.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| 41O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.9% | -11.3% | 3.0% |
| 1Y | -78.9% | -15.0% | 19.3% |
Return vs Industry: 41O underperformed the German Biotechs industry which returned -15% over the past year.
Return vs Market: 41O underperformed the German Market which returned 19.3% over the past year.
Price Volatility
| 41O volatility | |
|---|---|
| 41O Average Weekly Movement | 34.9% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 41O's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 41O's weekly volatility has increased from 20% to 35% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 23 | Larry Kenyon | www.outlooktherapeutics.com |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora.
Outlook Therapeutics, Inc. Fundamentals Summary
| 41O fundamental statistics | |
|---|---|
| Market cap | €52.60m |
| Earnings (TTM) | -€44.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.2x
P/E RatioIs 41O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 41O income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$46.89m |
| Gross Profit | -US$46.89m |
| Other Expenses | -US$82.98k |
| Earnings | -US$46.81m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -61.1% |
How did 41O perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/19 11:01 |
| End of Day Share Price | 2025/02/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Outlook Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Kumaraguru Raja | Brookline Capital Markets |